Compagnie Lombard Odier SCmA Buys 30,000 Shares of Pacific Biosciences of California (PACB)

Compagnie Lombard Odier SCmA lifted its holdings in Pacific Biosciences of California (NASDAQ:PACB) by 20.0% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 180,000 shares of the biotechnology company’s stock after purchasing an additional 30,000 shares during the period. Compagnie Lombard Odier SCmA owned 0.14% of Pacific Biosciences of California worth $366,000 as of its most recent filing with the SEC.

Other institutional investors have also bought and sold shares of the company. ARK Investment Management LLC increased its stake in shares of Pacific Biosciences of California by 516.0% in the fourth quarter. ARK Investment Management LLC now owns 213,917 shares of the biotechnology company’s stock worth $565,000 after purchasing an additional 179,192 shares during the period. Deutsche Bank AG grew its position in Pacific Biosciences of California by 87.1% during the fourth quarter. Deutsche Bank AG now owns 428,979 shares of the biotechnology company’s stock worth $1,131,000 after buying an additional 199,717 shares in the last quarter. Spark Investment Management LLC acquired a new stake in Pacific Biosciences of California during the fourth quarter worth about $704,000. Mutual of America Capital Management LLC grew its position in Pacific Biosciences of California by 5.9% during the fourth quarter. Mutual of America Capital Management LLC now owns 510,472 shares of the biotechnology company’s stock worth $1,348,000 after buying an additional 28,384 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in Pacific Biosciences of California by 6.6% during the fourth quarter. Geode Capital Management LLC now owns 932,575 shares of the biotechnology company’s stock worth $2,461,000 after buying an additional 57,374 shares in the last quarter. Institutional investors and hedge funds own 71.16% of the company’s stock.

Pacific Biosciences of California opened at $3.33 on Friday, according to MarketBeat Ratings. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.60 and a current ratio of 4.64. The company has a market cap of $418.05 million, a price-to-earnings ratio of -3.83 and a beta of 1.56. Pacific Biosciences of California has a 1-year low of $2.02 and a 1-year high of $5.70.



Pacific Biosciences of California (NASDAQ:PACB) last released its quarterly earnings data on Wednesday, May 2nd. The biotechnology company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). The company had revenue of $19.40 million for the quarter, compared to analyst estimates of $23.97 million. Pacific Biosciences of California had a negative net margin of 105.22% and a negative return on equity of 91.11%. The firm’s revenue for the quarter was down 22.1% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.26) earnings per share. sell-side analysts predict that Pacific Biosciences of California will post -0.63 EPS for the current year.

A number of research firms recently weighed in on PACB. Zacks Investment Research downgraded Pacific Biosciences of California from a “buy” rating to a “hold” rating in a research report on Friday, May 25th. BidaskClub raised Pacific Biosciences of California from a “sell” rating to a “hold” rating in a research report on Friday, April 13th. Finally, ValuEngine raised Pacific Biosciences of California from a “sell” rating to a “hold” rating in a research report on Saturday, June 2nd. Four equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $4.52.

Pacific Biosciences of California Profile

Pacific Biosciences of California, Inc designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company's single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. It offers PacBio RS II and Sequel Systems that conducts, monitors, and analyzes single molecule biochemical reactions in real time.

Institutional Ownership by Quarter for Pacific Biosciences of California (NASDAQ:PACB)

Receive News & Ratings for Pacific Biosciences of California Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacific Biosciences of California and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply